Home

JOSEF H VON RICKENBACH

CIK 1007706 · Chairman & CEO · last filed 2026-05-28

JOSEF H VON RICKENBACH is a Chairman & CEO who has filed 102 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing shows the insider bought $49.6K of RNTX on May 28, 2026. Across all open-market trades the lifetime net is −$28.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $45.3K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$45.3K

Companies

4

Total Filings

102

Lifetime Open-Market Net

-$28.10M

Filer Profile

Reported Address
C/O PAREXEL INTERNATIONAL CORPORATION
WALTHAM, MA 02451-1163
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
RNTX Director 58,014 $0.78 $45.3K $49.6K 2 2026-05-28
Rein Therapeutics, Inc. (ALRN) Delisted Director 22,273 $2.11 $47.0K $400.3K 13 2024-12-06
Virgin Orbit Holdings, Inc. (VORBW) Delisted 125,000 $0.01 $875 $0 1 2022-01-03
PAREXEL INTERNATIONAL CORP (PRXL) Delisted Chairman & CEO 503,329 — — -$28.55M 85 2017-09-18

Recent Filings

102 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-05-28 RNTX Buy (P) +47,060 $49.6K EDGAR
2025-07-23 RNTX Grant (A) — $0 EDGAR
2024-12-06 Rein Therapeutics, Inc. (ALRN) Delisted Grant (A) — $0 EDGAR
2024-08-22 Rein Therapeutics, Inc. (ALRN) Delisted Grant (A) — $0 EDGAR
2024-04-10 Rein Therapeutics, Inc. (ALRN) Delisted Grant (A) — $0 EDGAR
2024-03-01 Rein Therapeutics, Inc. (ALRN) Delisted Grant (A) — $0 EDGAR
2022-06-17 Rein Therapeutics, Inc. (ALRN) Delisted Grant (A) — $0 EDGAR
2022-01-03 Virgin Orbit Holdings, Inc. (VORBW) Delisted Grant (A) +125,000 $1.25M EDGAR
2021-06-17 Rein Therapeutics, Inc. (ALRN) Delisted Grant (A) — $0 EDGAR
2020-06-18 Rein Therapeutics, Inc. (ALRN) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 102
Page 1 of 11
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.